Navigation Links
Postmenopausal women with higher testosterone levels
Date:11/4/2009

Chevy Chase, MD Postmenopausal women who have higher testosterone levels may be at greater risk of heart disease, insulin resistance and the metabolic syndrome compared to women with lower testosterone levels, according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). This new information is an important step, say researchers, in understanding the role that hormones play in women's health.

"For many years, androgens like testosterone were thought to play a significant role in men only and to be largely irrelevant in women," said Anne Cappola, MD, of the University of Pennsylvania School of Medicine in Philadelphia. "It is now largely accepted that premenopausal women with polycystic ovary syndrome, a condition in which androgens are elevated, have increased health risks. However, the clinical relevance of testosterone in women over the age of 65 had remained uncertain until this recent study."

In this study, researchers measured levels of testosterone in 344 women, aged 65-98 years. They found that women with the highest testosterone levels in the top 25 percent of this study group were three times as likely to have coronary heart disease compared to women with lower testosterone levels. These women were also three times as likely to have a group of metabolic risk factors called the metabolic syndrome compared to women with lower testosterone levels.

The connection between higher levels of testosterone and these health risks may be explained by the researcher's finding of a greater degree of insulin resistance in women with the highest testosterone levels. Insulin resistance is a metabolic disturbance in which the body does not use insulin efficiently and is itself a risk factor for the metabolic syndrome and cardiovascular disease.

"Because of the observational aspect of this study, we cannot discern if testosterone is a marker or mediator of cardiovascular disease in this population," said Cappola. "Further studies are needed to determine if a causal relationship exists between testosterone and insulin resistance and to provide more insight into the role testosterone plays in the pathogenesis of cardiovascular disease in women."


'/>"/>

Contact: Aaron Lohr
alohr@endo-society.org
240-482-1380
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena(TM) (Ospemifene Tablets) in Treatment of Postmenopausal Vaginal Atrophy
2. QuatRx Announces Further Positive Phase 3 Results For Ophena(TM) (Ospemifene Tablets) in Postmenopausal Vaginal Atrophy
3. FDA Approves Reclast(R) to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing
4. Wyeths CONBRIZA Approved in the European Union for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
5. CONBRIZA Receives Positive CHMP Opinion for the Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
6. Exercise Boosts Quality of Life in Postmenopausal Women
7. Multivitamin use may offer no benefit in postmenopausal women
8. UNC study: Postmenopausal womens loss of sexual desire affects health, quality of life
9. High insulin levels raise risk of breast cancer in postmenopausal women
10. FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause
11. FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, ... relations, content marketing, social media management, corporate communications, SEO and cause marketing, is ... and in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding ...
(Date:2/23/2017)... ... 2017 , ... Pink Pig Publishing LLC announces the launch ... the world from different perspectives. By providing a place for people of all ... empathy, and find greater happiness. , "Our approach to structuring content is ...
(Date:2/23/2017)... RI (PRWEB) , ... February 23, 2017 , ... ... today a new partnership with the Rhode Island Consortium for Autism Research and ... an opportunity for children with autism spectrum disorder (ASD) to see films in ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today that the ... CM-AT in children aged 3-8 with Autism, is now enrolling at three new sites. ... across the United States. , “There are currently no approved drugs that address ...
(Date:2/22/2017)... Setauket, New York (PRWEB) , ... February 22, ... ... main floor entrance and lobby of a new healthcare contact center in Georgia, ... results. , One of the nation’s largest healthcare systems recently invested $51 million ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... On Wednesday, February 22, 2017, US ... of nine sectors finished the trading sessions in green, four ... Major US indices were also mixed at the close of ... slightly down by 0.09%; the Dow Jones Industrial Average edged ... closed at 2,362.82, down 0.11%. This Thursday morning, Stock-Callers.com looks ...
(Date:2/23/2017)... , February 23, 2017 Tillotts ... the Berlin office was opened ... Kritikos . The portfolio includes Entocort ® for ... the treatment of ulcerative colitis, and VistaPrep ® ... the Swiss specialty pharmaceutical company focused on the treatment ...
(Date:2/23/2017)... DIEGO , Feb. 23, 2017 ... a clinical-stage oncology drug development company, announces that ... and Drug Administration (FDA) authorizing the initiation a ... therapeutic treatment for pancreatic cancer. MVT-1075 ( 177 ... radioimmunotherapy (RIT). MabVax plans to initiate the phase ...
Breaking Medicine Technology: